Business
Glanbia : Q1 2026 Interim Management Statement (Glanbia Q1 IMS Presentation 2026)
Glanbia : Q1 2026 Interim Management Statement (Glanbia Q1 IMS Presentation
About this update from Glanbia Plc
Q1 2026 Interim Management Statement 2 9 A p r i l 2 0 2 6 Hugh McGuire Chief Executive Officer Mark Garvey Chief Financial Officer 2 0 2 6 Strong YTD Q1 performance with volume growth and continued positive momentum across all three segments Optimum Nutrition delivered +18.8% LFL revenue growth 1 driven by accelerating category growth, expanded distribution and innovation Q 1 Strong volume growth of +12.5% in H&N driven by demand across end-use markets of Active Nutrition, Functional Beverages and VMS Volume and pricing growth in protein solutions within Dairy Nutrition with overall LFL revenue growth +2.0% Continued progress on Group-wide transformation programme, targeting $60m+ annual savings by FY27, and €22.2m returned to shareholders via share buyback FY26 adjusted EPS 2 growth expected at the upper end of medium-term guidance of 7% to 11% 3 | Glanbia PLC Q1 2026 IMS Presentation 1 Like-for-like ("LFL") revenue growth shown on a constant currency basis. 2 Adjusted Earnings Per Share ("EPS") on a constant currency basis. PERFO RM ANCE NUTRI TI O N ( PN) Strong first quarter performance led by Optimum Nutrition Total revenue Q1 YTD 1 +1.3% Volume +9.2% Price +2.3% Disposals (10.2%) LFL revenue 2 +11.5% Volume +9.2% driven by accelerating category growth, new distribution, lapping of weaker comparative and innovation Pricing +2.3% with price increases implemented in the US in Q4 2025 somewhat offset by promotional activity and tactical price reductions on products in the energy category Optimum Nutrition LFL revenue growth of +18.8% and L13W US consumption 3 +13.3% with particularly strong growth in FDM/online channels New campaign, sponsorships and media partnerships driving engagement % of PN Revenue LFL Revenue Growth 2 Americas International 57% 43% +4.0% +23.4% 4 | Glanbia PLC Q1 2026 IMS Presentation 1 Revenue growth/decline shown on a constant currency basis versus Q1 2025. 2 LFL revenue growth shown on a constant currency basis. 3 Consumption based on US measured channels for the 13-week period to 4 April 2026. HEALTH & NUTRI TI O N ( H& N) Continued strong volume growth momentum driven by demand in end-use markets Total revenue Q1 YTD 1 +14.8% Volume +12.5% Price (0.9%) Acquisitions +3.2% H&N LFL 2 revenue growth of +11.6% Volume +12.5% driven by strong demand across priority end-use markets in Active Nutrition, Functional Beverages and VMS, with strong growth in EMEA and ASPAC Pricing -0.9% driven by pass-through pricing with customers Integration of Sweetmix and Scicore on track and capacity expansions in Asia, Europe and the US underway 5 | Glanbia PLC Q1 2026 IMS Presentation 1 Revenue growth/decline shown on a constant currency basis versus Q1 2025. 2 LFL revenue growth shown on a constant currency basis. DAI RY NUTRI TI O N ( DN) Strong performance through volume and pricing in Protein Solutions Total revenue Q1 YTD 1 +2.0% Volume +6.4% Price (4.4%) LFL 2 revenue growth of +2.0% Volume +6.4% driven by continued strong demand for protein solutions and bioactives with demand for high-end whey proteins remaining robust Pricing -4.4% reflects strong whey protein markets offset by negative cheese markets Continued demand for colostrum bioactives, targeting gut health and immunity Additional WPI capacity via Joint Venture on track 6 | Glanbia PLC Q1 2026 IMS Presentation 1 Revenue growth/decline shown on a constant currency basis versus Q1 2025. 2 LFL revenue growth shown on a constant currency basis. STRONG BALANCE SHEET D E B T C A P I T A L E X P E N D I T U R E S H A R E H O L D E R R E T U R N S Net Debt $648m Total committed facilities of $1.4bn FY26 capex expected to be $100m - $110m €100m share buyback authorisation €22.2m returned via share buyback programme 1 to date Final dividend 25.67 €cent 7 | Glanbia PLC Q1 2026 IMS Presentation 1 Between 25 February 2026 and 27 April 2026. FY 26 OUTLOOK ALIGNED WITH MEDIUM - TERM GROWTH ALGORITHM Revenue growth: upper end of +5-7% EBITDA margin progression Revenue growth: upper end of +4-6% EBITDA margin: 17-19% EBITDA in the range of $160-170m (above medium-term guidance) Adj. EPS 1 at upper end of 7% - 11% OCF Conversion 85%+ 8 | Glanbia PLC Q1 2026 IMS Presentation 1 On a constant currency basis. DELIVERING BETTER NUTRITION 1 High-growth categories with leading brands and ingredients driven by consumer megatrends 2 Sharpened and focused operating model and portfolio to capture the growth 3 Our people, portfolio, and firepower will continue to drive strong shareholder returns 9 | Glanbia PLC Q1 2026 IMS Presentation A P E R F O R M A N C E D R I V E N P U R P O S E L E D G L O B A L N U T R I T I O N C O M P A N Y 10 | Glanbia PLC Q1 2026 IMS Presentation Attention : This is an excerpt of the original content. To continue reading it, access the original document here .